Breast Cancer Research and Treatment

, Volume 6, Issue 1, pp 49–56

Tumor-associated antigen TAG-72: Correlation of expression in primary and metastatic breast carcinoma lesions

  • S. Chace Lottich
  • William W. Johnston
  • Cheryl A. Szpak
  • Elizabeth R. Delong
  • Ann Thor
  • Jeffrey Schlom


Variability of tumor-associated antigens among and within human tumor cell groups presents a potential problem in the development and optimization of immunodiagnostic and therapeutic procedures for cancer. We determined the degree of expression of a tumor-associated antigen in the primary and metastatic lesions of 23 patients with infiltrating ductal carcinoma; this was accomplished using monoclonal antibody B72.3, an IgG1 generated against membrane-enriched fractions of human metastatic breast carcinomas and reactive with a 220,000–400,000 d glycoprotein complex, termed TAG-72, and the avidin-biotin complex immunoperoxidase method on fixed tissue sections. Sixteen of the 23 breast carcinomas (70%) demonstrated MAb B72.3 reactivity (range 5% to 100% of tumor cells staining). Reactivity of lymph node metastases was present in 14 of 21 patients (67%). MAb reactivity in metastases to distant sites, including bone, adrenals, liver, skin and effusions, was present in 10 of 18 patients (56%). In one patient, neither the primary carcinoma nor the metastasis to the lymph node demonstrated reactivity. There was a statistically significant positive correlation between MAb B72.3 reactivity in both primary and lymph node metastases (Kendall's Correlation Coefficient = 0.60, p = 0.0006) and between lymph node and distant metastases (Kendall's Correlation Coefficient = 0.48, p = 0.02) of the same patient. No correlation existed between antibody reactivity seen in the primary and that found in the distant lesions of that patient. These studies thus demonstrate that monoclonal antibody B72.3 can detect expression of a tumor-associated antigen in both primary and metastatic infiltrating ductal carcinoma lesions, and may prove valuable in the understanding of tumor biology of metastases and as a means for diagnosing occult disease.

Key words

breast cancer monoclonal antibody tumor-associated antigen 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    CA-A Cancer Journal for Clinicians. (Am Cancer Soc) 34:7, 1984Google Scholar
  2. 2.
    Colcher D, Horan Hand P, Nuti M, Schlom J: A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 78:3199–3203, 1981PubMedGoogle Scholar
  3. 3.
    Nuti M, Teramoto Y, Mariani-Costantini R, Horan Hand P, Colcher D, Schlom J: A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int J Cancer 29:539–545, 1982PubMedGoogle Scholar
  4. 4.
    Stramignoni D, Bowen R, Atkinson BF, Schlom J: Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. Int J Cancer 31:543, 1983PubMedGoogle Scholar
  5. 5.
    Szpak C, Johnston W, Lottich S, Kufe D, Thor A, Schlom J: Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1, and B6.2) with cells in human malignant and benign effusions. Acta Cytol 28:356–367, 1984PubMedGoogle Scholar
  6. 6.
    Johnston WW, Szpak CA, Lottich SC, Thor A, Schlom J: Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions. Cancer Research (in press)Google Scholar
  7. 7.
    Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC: The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (Protocol No. 4). Cancer 36:1–85, 1975PubMedGoogle Scholar
  8. 8.
    Herzenberg LA, Herzenberg LA, Milstein C:In Weir DM (ed): Handbook of Experimental Immunology. Blackwell Scientific, London, 1979, pp 25.1–25.7Google Scholar
  9. 9.
    Colcher D, Horan Hand P, Nuti M, Schlom J: Differential binding to human mammary and non-mammary tumors of monoclonal antibodies reactive with carcinoembryonic antigen. Cancer Invest 1:127–138, 1983PubMedGoogle Scholar
  10. 10.
    Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PPA) procedures. J Histochem Cytochem 29:577–580, 1981PubMedGoogle Scholar
  11. 11.
    Luna LG (ed): Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology, 3rd Edition. McGraw-Hill, New York, 1968, pp. 41–42.Google Scholar
  12. 12.
    Horan Hand P, Nuti M, Colcher D, Schlom J: Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumor associated antigens. Cancer Res 43:728–735, 1983PubMedGoogle Scholar
  13. 13.
    Colnaghi MI, Canevari S, Torre GD, Menard S, Miotti S, Regazzoni M, Tagliabue E: Monoclonal antibodies potentially useful in clinical oncology.In Boss BD, Langman R, Trowbridge I, Dulbecco R (eds): Monoclonal Antibodies and Cancer. Academic Press, Orlando, 1983, pp 207–213Google Scholar
  14. 14.
    Koprowski H: Mouse monoclonal antibodies in vivo.In Boss BD, Langman R, Trowbridge I, Dulbecco R (eds): Monoclonal Antibodies and Cancer. Academic Press, Orlando, 1983, pp 17–38Google Scholar

Copyright information

© Martinus Nijhoff Publishers 1985

Authors and Affiliations

  • S. Chace Lottich
    • 1
  • William W. Johnston
    • 2
  • Cheryl A. Szpak
    • 2
  • Elizabeth R. Delong
    • 3
  • Ann Thor
    • 4
  • Jeffrey Schlom
    • 4
  1. 1.Department of SurgeryDuke University Medical CenterDurhamUSA
  2. 2.Department of PathologyDuke University Medical CenterDurhamUSA
  3. 3.Department of Health ServiceSearch Field Program, Veterans AdministrationDurhamUSA
  4. 4.Laboratory of Tumor Immunology and BiologyNational Cancer InstituteBethesdaUSA
  5. 5.Duke University Medical CenterDurhamUSA

Personalised recommendations